Journal
JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS
Volume 44, Issue 10, Pages 2525-2535Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10803-014-2123-9
Keywords
Insomnia; N-acetylserotonin; Dim light melatonin onset
Categories
Funding
- NCRR NIH HHS [M01 RR000095, M01 RR-00095] Funding Source: Medline
- NICHD NIH HHS [R01HD59253, HD15052, P30 HD015052, R01 HD059253] Funding Source: Medline
Ask authors/readers for more resources
Supplemental melatonin has been used to treat sleep onset insomnia in children with autism spectrum disorders (ASD), although the mechanism of action is uncertain. We assessed endogenous and supplemental melatonin profiles in relation to sleep in nine children with ASD. In endogenous samples, maximal melatonin concentration (C (max)) and time to peak concentration (T (max)) were comparable to those previously published in the literature for typically developing children, and dim light melatonin onsets were captured in the majority of children. In treatment samples (supplemental melatonin), melatonin parameters were also comparable to those previously published for typically developing children. Our findings support that children with ASD and insomnia responsive to low dose melatonin treatment have relatively normal profiles of endogenous and supplemental melatonin.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available